Skip to Content

Nicox SA NICXF

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Nicox SA is a France based ophthalmic corporation. It is focused on operating in the ophthalmic market through a diversified portfolio of ophthalmic products. The company’s pipeline features VESNEO for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension; AC-170 for the treatment of ocular itching associated with allergic conjunctivitis; AzaSite for bacterial conjunctivitis; and BromSite for pain and inflammation after cataract surgery. The group operates internationally and is also focused on developing a pipeline of ophthalmology-focused candidates which utilize its proprietary nitric oxide-donating research platform.

Contact
Drakkar 2 - Batiment D, 2405 route des Dolines - CS 10313
Sophia Antipolis Cedex, 06560, France
T +33 497245300
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Dec 31, 2013
Fiscal Year End Dec 31, 2019
Stock Type
Employees 34